Evidence map›Paper›PMID 37859721›Full record

ArticleRSC medicinal chemistry2023

Development of anti-HBV agents targeting HBV capsid proteins.

Takuya Kobayakawa, Masayuki Amano, Miyuki Nakayama, Kohei Tsuji, Takahiro Ishii, Yutaro Miura, Kouki Shinohara, Kenichi Yamamoto, Masao Matsuoka, Hirokazu Tamamura

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Takuya KobayakawaInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.ORCID https://orcid.org/0000-0001-9786-2608
Masayuki AmanoDepartment of Clinical Retrovirology, Joint Research Center for Human Retrovirus Infection, Kumamoto and Kagoshima Universities Kumamoto 860-0811 Japan.ORCID https://orcid.org/0000-0003-0516-9502
Miyuki NakayamaInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.
Kohei TsujiInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.ORCID https://orcid.org/0000-0003-4773-8793
Takahiro IshiiInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.ORCID https://orcid.org/0000-0003-1664-6191
Yutaro MiuraInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.
Kouki ShinoharaInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.
Kenichi YamamotoInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.
Masao MatsuokaDepartment of Hematology, Rheumatology, and Infectious Diseases, Faculty of Life Sciences, Kumamoto University Kumamoto 860-8556 Japan.
Hirokazu TamamuraInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.ORCID https://orcid.org/0000-0003-2788-2579
Tokyo Medical and Dental University · JPKumamoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B is a viral hepatitis, which is caused by infection of hepatitis B virus (HBV). This disease progresses to chronic hepatitis, cirrhosis and liver cancer. To treat hepatitis B, exclusion of virus and covalently closed circular DNA (cccDNA) that is formed in hepatocyte nucleus is necessary. A hepatitis B capsid protein (HBc) is an indispensable protein, which forms the capsid that encapsulates viral DNA. Since HBc is correlated to the transcriptional regulation of cccDNA, this protein would be an attractive target for complete cure of hepatitis B. By

Identifiers

PMID37859721
PMCPMC10583812
OpenAlexW4386144565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.